{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T06:33:05Z","timestamp":1772951585205,"version":"3.50.1"},"posted":{"date-parts":[[2025,11,17]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":27,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Timely initiation of antivirals for SARS CoV 2 and influenza depends on rapid diagnosis and access to prescribing. A national home based test to treat service was implemented to address these barriers.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate reach, use, and timeliness of prescribing in the Home Test to Treat program.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Observational cohort analysis of program data from August 15, 2023 through April 17, 2024. Multivariable models assessed factors associated with test kit receipt, telehealth use and timing from symptom onset, antiviral prescribing and timing, and modality of medication fulfillment.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Nationwide, remote program providing free at home tests, on demand telehealth, and oral antivirals with pharmacy pickup or home delivery.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>66,169 adults who enrolled in the program and were eligible for analysis. Participation pathways included 1) proactive testing before symptoms, 2) on demand testing after symptom onset without a diagnosis, and 3) treatment only after a positive test.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Exposures<\/jats:title>\n                  <jats:p>Program pathway and participant characteristics, including insurance status and prior difficulties accessing care.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Main Outcomes and Measures<\/jats:title>\n                  <jats:p>Receipt of test kits, telehealth use and timing from symptom onset, and prescription of guideline directed oral antivirals within 1 day and within 5 days of symptom onset; choice of home delivery versus local pharmacy pickup.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Enrollees represented all 50 states and 891 of 896 three-digit ZIP Code areas. Proactive testers comprised 52.6%; 15.0% of the analytical sample reported a positive result. Among positives, 80.7% used the treatment only pathway; 83.2 percent chose telehealth and 76.3% of consults occurred outside local business hours. Antivirals were prescribed to 6,821 enrollees; 59.8% received oral antivirals within 1 day and 92.8% within 5 days of symptom onset. Prescribing within 1 day did not differ notably by age, insurance, race or ethnicity, or prior difficulty accessing care. Of those prescribed, 1,092 enrollees, 16.0%, selected home delivery rather than pharmacy pickup. Home delivery was more common among enrollees reporting more reasons for delaying care, difficulty accessing care, lacking insurance, or enrolled in Medicaid (P &lt; .05).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions and Relevance<\/jats:title>\n                  <jats:p>Home Test to Treat delivered timely prescribing, including for adults with prior access barriers, by combining home based testing, on demand telehealth, and options for medication delivery across the country.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>Does a national home test-to-treat program deliver timely antiviral treatment for COVID-19 and influenza across diverse adults?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Among 66,169 enrollees in all 50 states, 83% of positives used telehealth; 82% received antivirals; 60% were treated within 1 day and 93% within 5 days of symptoms; most visits occurred outside business hours; timeliness did not differ meaningfully by age, insurance, or race\/ethnicity once enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Meaning<\/jats:title>\n                    <jats:p>An integrated home testing and on-demand telehealth pathway achieved rapid, equitable treatment at national scale and provides a practical model to strengthen access and preparedness.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2025.11.13.25339276","type":"posted-content","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T07:05:19Z","timestamp":1763449519000},"source":"Crossref","is-referenced-by-count":0,"title":["Primary Findings of Nationwide Home-based Test to Treat Program for COVID-19 and Influenza"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-3657","authenticated-orcid":false,"given":"Apurv","family":"Soni","sequence":"first","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqi","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deogwoon","family":"Kim","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Pretz","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Dunkel","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Israel","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben S.","family":"Gerber","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Hsien","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen","family":"Weaver","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carly","family":"Herbert","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Hafer","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pragna","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Mazor","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Fisher","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Weitz","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025111906412270000_2025.11.13.25339276v1.1","unstructured":"Hill L , Artiga S , Rouw A , Kates J . How Equitable is Access to COVID-19 Treatments? KFF. June 23, 2022. Accessed November 8, 2025. https:\/\/www.kff.org\/covid-19\/how-equitable-is-access-to-covid-19-treatments\/"},{"key":"2025111906412270000_2025.11.13.25339276v1.2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7125e1"},{"key":"2025111906412270000_2025.11.13.25339276v1.3","unstructured":"Murphy SJ , Samson W , Sommers BD . COVID-19 Antivirals Utilization: Geographic and Demographic Patterns of Treatment in 2022. Published online 2022. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/a19600d0dccfee0e9c595730d73fd66d\/covid-antivirals-report.pdf"},{"key":"2025111906412270000_2025.11.13.25339276v1.4","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7303a2"},{"key":"2025111906412270000_2025.11.13.25339276v1.5","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5044"},{"key":"2025111906412270000_2025.11.13.25339276v1.6","doi-asserted-by":"crossref","unstructured":"Shen Y , Robertson MM , Kulkarni SG , et al. Oral COVID-19 antiviral uptake among a highly vaccinated US cohort of adults with SARS-CoV-2 infection between December 2021 and October 2022. Open Forum Infect Dis. 2024;11(2):ofad674.","DOI":"10.1093\/ofid\/ofad674"},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.7","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1038\/s41467-022-32640-2","article-title":"The impact of repeated rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2","volume":"13","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","year":"2023","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"2025111906412270000_2025.11.13.25339276v1.9","doi-asserted-by":"crossref","first-page":"e2241144","DOI":"10.1001\/jamanetworkopen.2022.41144","article-title":"Geographic accessibility of COVID-19 test to treat sites by race, ethnicity, age, and rurality","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2025111906412270000_2025.11.13.25339276v1.10","first-page":"e0036723","article-title":"RADx-UP Testing Core: Access to COVID-19 diagnostics in community-engaged research with Underserved Populations","volume":"61","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2025111906412270000_2025.11.13.25339276v1.11","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.26.22272727"},{"issue":"6","key":"2025111906412270000_2025.11.13.25339276v1.12","doi-asserted-by":"crossref","first-page":"e38113","DOI":"10.2196\/38113","article-title":"Design and Preliminary Findings of Adherence to the Self-Testing for Our Protection From COVID-19 (STOP COVID-19) Risk-Based Testing Protocol: Prospective Digital Study","volume":"6","year":"2022","journal-title":"JMIR Form Res"},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1186\/s12889-021-12007-w","article-title":"At-home testing to mitigate community transmission of SARS-CoV-2: protocol for a public health intervention with a nested prospective cohort study","volume":"21","year":"2021","journal-title":"BMC Public Health"},{"key":"2025111906412270000_2025.11.13.25339276v1.14","doi-asserted-by":"crossref","unstructured":"Singler L , Uhlenbrauck G , Corbie-Smith G , et al. Say Yes! COVID test: A health communication campaign to encourage use of rapid, at-home antigen testing in underserved and historically marginalized communities. Inquiry. 2023;60:469580221146046.","DOI":"10.1177\/00469580221146046"},{"key":"2025111906412270000_2025.11.13.25339276v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/cat.22.0328"},{"key":"2025111906412270000_2025.11.13.25339276v1.16","unstructured":"COVID-19 Oral Antivirals: Overcoming Barriers to Access and Education. https:\/\/cveep.org\/wp-content\/uploads\/2023\/07\/CVEEP_OAV-Literature-Review-EN_0624.pdf"},{"key":"2025111906412270000_2025.11.13.25339276v1.17","unstructured":"The White House. FACT SHEET: Biden Administration Announces Launch of First Federally-Supported Test to Treat Site. The White House. May 26, 2022. Accessed November 8, 2025. https:\/\/bidenwhitehouse.archives.gov\/briefing-room\/statements-releases\/2022\/05\/26\/fact-sheet-biden-administration-announces-launch-of-first-federally-supported-test-to-treat-site\/"},{"key":"2025111906412270000_2025.11.13.25339276v1.18","unstructured":"NIH launches Home Test to Treat, a pilot COVID-19 telehealth program. National Institute of Biomedical Imaging and Bioengineering. Accessed November 8, 2025. https:\/\/www.nibib.nih.gov\/news-events\/newsroom\/nih-launches-home-test-treat-pilot-covid-19-telehealth-program"},{"issue":"8","key":"2025111906412270000_2025.11.13.25339276v1.19","doi-asserted-by":"crossref","first-page":"e2331249","DOI":"10.1001\/jamanetworkopen.2023.31249","article-title":"Anti-SARS-CoV-2 pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023","volume":"6","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025111906412270000_2025.11.13.25339276v1.20","unstructured":"Racial and Ethnic Disparities in Outpatient Treatment of COVID-19-United States."},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40249-021-00835-2","article-title":"Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study","volume":"10","year":"2021","journal-title":"Infect Dis Poverty"},{"issue":"4","key":"2025111906412270000_2025.11.13.25339276v1.22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/ijms22041737","article-title":"Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics","volume":"22","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41479-025-00168-w","article-title":"Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave: a US-based propensity-matched cohort study","volume":"17","year":"2025","journal-title":"Pneumonia (Nathan)"},{"issue":"11","key":"2025111906412270000_2025.11.13.25339276v1.24","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v14112514","article-title":"Early access to oral antivirals in high-risk outpatients: Good weapons to fight COVID-19","volume":"14","year":"2022","journal-title":"Viruses"},{"key":"2025111906412270000_2025.11.13.25339276v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2118542"},{"issue":"1","key":"2025111906412270000_2025.11.13.25339276v1.26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/M22-2141","article-title":"Nirmatrelvir plus ritonavir for early COVID-19 in a large U.s. health system : A population-based cohort study: A population-based cohort study","volume":"176","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025111906412270000_2025.11.13.25339276v1.27","unstructured":"Rural Health Transformation (RHT) Program. Accessed November 8, 2025. https:\/\/www.cms.gov\/priorities\/rural-health-transformation-rht-program\/overview"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.13.25339276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T18:15:16Z","timestamp":1772907316000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.11.13.25339276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1101\/2025.11.13.25339276","relation":{},"subject":[],"published":{"date-parts":[[2025,11,17]]},"subtype":"preprint"}}